Previous studies have shown that FGFR3 mutations are encountered more frequently in luminal tumors, which are known to be comparatively less responsive to checkpoint inhibition, and that FGFR3-mutated bladder tumors are associated with decreased T-cell infiltration and low PD-L1 expression [15], [16], [17]. This evidence concerns the gene FGFR3 and urinary bladder neoplasm.